Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (3265)	12/9/1997 9:03:00 PM
From: JOHN W.	Respond to of 6136

Title: Perinatal AIDS Program Reports Success With Combination Therapy Source: Reuters Health Information Services (12/08/97) Abstract: The Bay Area Perinatal AIDS Center, an affiliate of the University of California at San Francisco, has had great success in preventing the perinatal transmission of HIV to infants. Since April 1995, none of the 56 HIV-positive women treated at the center have delivered an infected infant. The program prevents transmission of the disease by offering counseling, support, and monitoring, as well as combination antiretroviral therapies. According to Karen Beckerman, program director, the center's use of combination drug therapies is the primary reason for its success.